Document is current
Any future updates will be listed below
-
Authors
Schlesinger, Naomi https://orcid.org/0000-0002-1558-1202
Padnick-Silver, Lissa https://orcid.org/0000-0002-4199-4844
LaMoreaux, Brian https://orcid.org/0000-0001-7521-241X
-
Funding
Funding for this research was provided by:
Horizon Therapeutics plc
- License Information
-
More Information
Article History
Accepted: 25 January 2022
First Online: 22 March 2022
Declarations
:
: Manuscript development was supported by Horizon Therapeutics plc (Deerfield, IL, USA).
: NS has received grants from Amgen and is a consultant to and advisory board member for Horizon Therapeutics, Alnylam Pharmaceuticals, and JW Pharmaceutical Corporation. BL and LP-S are employees of and stockholders in Horizon Therapeutics.
: Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
: Not applicable.
: This review did not involve the collection or analysis of new data and only examined data already published in the literature.
: Not applicable.
: This review only contains aggregate findings from published studies and does not contain individual patient data.
